Anaphylaxis represents a medical emergency where seconds determine outcomes, and glucagon has established itself as a critical intervention for specific patient populations. This overview details the physiological role of glucagon, its mechanism during anaphylactic shock, and the clinical protocols guiding its use when first-line therapies face limitations.
Understanding Anaphylaxis and Standard Treatment
Anaphylaxis is a systemic, life-threatening allergic reaction characterized by rapid onset of respiratory distress and cardiovascular collapse. The primary treatment focuses on epinephrine, which rapidly reverses bronchoconstriction, vasodilation, and mucosal edema. However, certain clinical scenarios, such as patients on beta-blockers or with cardiovascular instability, may present challenges where adjunct therapies become essential considerations.
The Role of Glucagon in Emergency Medicine
Glucagon is a hormone produced by the alpha cells of the pancreas, primarily responsible for stimulating hepatic glycogenolysis to increase blood glucose levels. In the context of anaphylaxis, its utility extends beyond glycemic control due to its inotropic and chronotropic effects on the heart. It bypasses beta-adrenergic receptors, making it a valuable agent when standard epinephrine therapy is compromised by beta-blocker use.
Mechanism of Action in Cardiovascular Support
During anaphylaxis, massive vasodilation and increased vascular permeability lead to hypotension and shock. Glucagon activates adenylate cyclase via a G-protein pathway, independent of the beta-receptor pathway typically targeted by epinephrine. This results in increased intracellular cyclic AMP, enhancing cardiac contractility and heart rate, thereby supporting blood pressure and organ perfusion without relying on the blocked adrenergic system.
Clinical Indications and Patient Selection
While epinephrine remains the gold standard, glucagon is indicated as an adjunctive therapy in specific situations. The primary indication is anaphylaxis in patients who are concurrently taking non-selective beta-blockers. In these cases, beta-adrenergic receptors are occupied, rendering epinephrine less effective on the myocardium, where glucagon can provide the necessary cardiac stimulation.
Patients on chronic beta-blocker therapy experiencing anaphylaxis.
Cases of refractory hypotension despite adequate epinephrine dosing.
Institutions with established protocols and readily available glucagon formulations.
Dosing Protocols and Administration
Intramuscular glucagon is the preferred initial route in emergency settings, offering a balance between speed of delivery and ease of use. Intravenous administration requires careful titration due to the risk of precipitating tachycardia or hypertension. Protocols vary, but typical dosing for adults involves an initial bolus followed by a continuous infusion to maintain hemodynamic stability.
Route | Adult Dose | Onset of Action | Duration
Intramuscular (IM) | 1 mg (up to 2 mg) | 5–10 minutes | 60–90 minutes
Intravenous (IV) | 1–2 mg bolus, then infusion | 1–2 minutes | Dependent on infusion
